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Summary
Interleukin (IL)-6 is a multifunctional cytokine with
diverse actions and has been implicated in the patho-
physiology of many neurological and in¯ammatory
disorders. In this study, we investigated the role of IL-6
in pneumococcal meningitis. Cerebral infection in
wild-type (WT) mice caused an increase in vascular
permeability and intracranial pressure (ICP), which
were signi®cantly reduced in IL-6±/± mice. In contrast,
meningitis in IL-6±/± mice was associated with a signi®-
cant increase in CSF white blood cell count compared
with infected WT mice, indicating an enhanced in¯am-
matory response. Analysis of mRNA expression in the
brain showed an increase in tumour necrosis factor
(TNF)-a, IL-1b, and macrophage in¯ammatory
protein 2 (MIP-2) levels, but decreased expression of
granulocyte±macrophage colony-stimulating factor in
infected IL-6±/± mice compared with infected WT con-
trols. Similar results were obtained when rats
challenged with pneumococci were systemically treated
with neutralizing anti-IL-6 antibodies, resulting in an
increased pleocytosis but at the same time a reduction
of vascular permeability, brain oedema formation, and
ICP, which was not accompanied by a downregulation
of matrix metalloproteinases. Our data indicate that
IL-6 plays an important anti-in¯ammatory role in bac-
terial meningitis by reducing leukocyte in®ltration but
contributes to the rise in intracranial pressure by
increasing blood±brain barrier (BBB) permeability.
These ®ndings suggest that the migration of leukocytes
across the BBB and the increase in vascular permeabil-
ity are two independent processes during bacterial
meningitis.
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Introduction
Bacterial meningitis is associated with a high morbidity and
mortality (Quagliarello and Scheld, 1992). The reasons for
the unfavourable clinical outcome include cerebrovascular
alterations, breakdown of the blood±brain barrier (BBB),
formation of vasogenic brain oedema and increase in
intracranial pressure (ICP) (P®ster et al., 1992). Several
mediators of the pathophysiological pathway contributing to
these intracranial complications have been identi®ed, includ-
ing nitric oxide (Koedel et al., 1995), reactive oxygen species
(Koedel and P®ster, 1999) and matrix metalloproteinases
(MMPs) (Paul et al., 1998). Moreover, experimental and
clinical studies suggest that cytokines including tumour
necrosis factor (TNF)-a (Nadal et al., 1989) and interleukin
(IL)-1b (Quagliarello et al., 1991), and chemokines such as
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macrophage in¯ammatory protein 2 (MIP-2) (Diab et al.,
1999), also play an important role in the pathophysiology of
bacterial meningitis.
IL-6 is a multifunctional cytokine with diverse actions, e.g.
regulation of in¯ammation including the induction of the
acute phase reaction, immune response and cellular differ-
entiation (Gadient and Otten, 1997). Increased cerebral
expression of IL-6 has been demonstrated in many CNS
diseases, such as HIV encephalopathy, multiple sclerosis and
Alzheimer's disease (Gadient and Otten, 1997). High levels
of IL-6 were also detected in the CSF of patients with viral
and bacterial meningitis (Houssiau et al., 1988; Matsuzono
et al., 1995). In a previous study using a rat model of
pneumococcal meningitis we found elevated concentrations
of IL-6 in the CSF 6 h after challenge (Koedel et al., 1996).
However, the precise role of IL-6 in the pathophysiology of
in¯ammatory and CNS diseases has not been elucidated. On
one hand, IL-6 was reported to have bene®cial effects by
reducing neuronal damage in cerebral ischaemia (Loddick
et al., 1998), preventing cartilage destruction during experi-
mental arthritis (van de Loo et al., 1997), and acting as an
anti-in¯ammatory cytokine in endotoxemia (Xing et al.,
1998). On the other hand, transgenic mice lacking the IL-6
gene were resistant to the pathophysiological alterations in
experimental autoimmune encephalomyelitis (Eugster et al.,
1998), and mice overexpressing IL-6 in astrocytes showed
neuropathological abnormalities with a breakdown of the
BBB (Brett et al., 1995), suggesting a detrimental role of IL-6
in neurological diseases associated with increased BBB
permeability.
The aim of this study was to investigate the impact of IL-6
on the pathophysiology of pneumococcal meningitis using
IL-6±/± mice as well as neutralizing anti-IL-6 antibodies in a
rat model. We demonstrate that during bacterial meningitis
IL-6 acts as an anti-in¯ammatory cytokine by suppressing the
transmigration of leukocytes into the CSF space, but plays a
major role in the increase of vascular permeability, causing
brain oedema and increase in ICP, indicating that these are
two independent processes.
Material and methods
Mouse model of pneumococcal meningitis
All of the experiments were approved by the government of
Upper Bavaria. Sixteen male and female mice were used in
this study. C57BL/6 mice were purchased from Charles River
(Sulzfeld, Germany). The IL-6±/± mice, backcrossed into
C57BL/6 mice, were a kind gift from Hoffmann-La Roche
Ltd (Basel, Switzerland). For induction of bacterial menin-
gitis the mice were short-term anesthetized with halothan
(Hoechst AG, Frankfurt/M, Germany) and 15 ml 107 colony
forming units/ml of Streptococcus pneumoniae strain type 3
were injected transcutaneously into the cisterna magna.
Control mice received 15 ml of phosphate-buffered saline
(PBS) intracisternally (i.c.), instead of pneumococci. The
mice were housed individually in cages, allowed to wake up
naturally, and fed with a standard diet and water ad libitum.
After 24 h the mice were anesthetized intraperitoneally
(i.p.) with 100 mg/kg chloralhydrate, and the left femoral vein
was cannulated for ¯uid substitution and the administration of
Evan's Blue (EB) dye. The body temperature of the mice was
kept constant at 37.5 6 0.5°C using a rectal thermometer-
controlled heating pad. A burr hole was made at the occipital
bone and a catheter was inserted into the cisterna magna for
ICP monitoring and collection of CSF samples to determine
CSF white blood cell (WBC) count at the end of the
experiment.
Determination of BBB permeability in the
mouse model
BBB permeability was determined as described previously by
Gijbels et al. (1994). Mice were injected intravenously with
0.1 ml of 1% (w/v) EB. After 1 h the brains were perfused
with 10 ml of ice-cold PBS and removed. The brains were
weighed and tissue samples were extracted for 3 days in
formamide (5 ml/mg tissue) and the extract centrifuged for
5 min at 500 g. EB concentration in the supernantants was
determined by measuring the absorbance at 650 nm. The
BBB permeability index was calculated by dividing the value
for each sample by the mean value of the control animals.
Mouse intracerebral injection and determination
of BBB disruption
Determination of the effect of IL-6 on cerebral vascular
permeability was performed as previously described (Paul
et al., 2001). Recombinant human IL-6 (Biosource,
Cammarillo, CA, USA) was injected stereotactically into
the left frontal lobe (1.5 mm left and 0.5 mm rostral from
bregma, 2.5 mm in depth from the dura) of C57BL/6 mice.
PBS was injected into the right hemisphere as a control. The
animals received 100 ml of a 2% EB solution intravenously
15 min after IL-6 injection. After additional 45 min, the
brains were perfused with PBS and removed. Whole-mount
direct EB ¯uorescence was observed using confocal micro-
scopy of fresh in®xed brains.
Detection of mouse mRNA levels by RT-PCR
Frozen brains from IL-6±/± (n = 3) and wild-type (WT) mice
(n = 3) were cut with a cryostat. Total RNA was prepared
from frozen sections containing lateral ventricules and
hippocampal tissue with Trizol-LS-reagent (Gibco-BRL,
Gaithersburg, MD, USA). Oligo(dt)-primed cDNA was
prepared from 5 mg total RNA using Superscript II reverse
transcriptase (Gibco-BRL) as recommended by the manu-
facturer. Speci®c primers were designed for granulocyte±
macrophage colony-stimulating factor (GM-CSF) (sense 5¢-
TTC CTG GGC ATT GTG GTC T-3¢; antisense 5¢-TGG ATT
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CAG AGC TGG CCT GG-3¢), MIP-2 (sense 5¢-AGT TTG
CCT TGA CCC TGA AGC C-3¢; antisense 5¢-TGG GTG
GGA TGT AGC TAG TTC C-3¢), b-actin (sense 5¢-GGA
CTC CTA TGT GGG TGA CGA GG-3¢; antisense 5¢-GGG
AGA GCA ATA GCC CTC GTA AGA T-3¢) and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
(sense 5¢-CAT CAC CAT CTT CCA GGA GCG-3¢; antisense
5¢-GAG GGG CCA TCC ACA GTC TTC-3¢).
Of the cDNA product, 1.0 ml (corresponding to 125 ng
RNA) was used for PCR in a reaction mix (40 ml) consisting
of 0.18 U Taq DNA polymerase (Amplitaq Gold; Perkin
Elmer, Foster City, CA, USA), 1 mM of each primer, 0.2 mM
dNTP mix, 2.5 mM MgCl2 and 4.0 ml of 103 PCR buffer.
Negative controls with RNA before reverse transcription
were performed to ensure cDNA ampli®cation. PCR was
performed in an Eppendorf thermocycler using the following
pro®le: denaturation at 94°C for 30 s, annealing at individual
temperatures (61±66°C) for 30 s and elongation at 72°C for
1 min 30 s. The 25 cycles (GAPDH), 35 cycles (MIP-2) and
40 cycles (GM-CSF) used were in the linear range of
ampli®cation. PCR products were seperated on a 1.7%
agarose gel and stained with ethidium bromide. Photographs
were scanned and analysed by densitometry. PCR was carried
out in duplicate and the mean of product density was
expressed relative to GAPDH and b-actin controls, respect-
ively. Speci®ty of PCR products was con®rmed by DNA
sequencing. The mRNA expression ratio between infected
and uninfected mice was calculated by dividing the value for
each sample of an infected mouse by the mean value of
the uninfected mice. All experiments were performed in
duplicate.
Rat model of pneumococcal meningitis
A modi®cation of a well-established rat model of pneumo-
coccal meningitis was used for the experiments which was
previously described in detail (Koedel and P®ster, 1997).
Thirty-one adult male Wistar rats (Charles River) were used
in this study. For induction of bacterial meningitis the rats
were short-termed anesthetized with halothan (Hoechst AG)
and 150 ml 107 colony forming units/ml of Streptococcus
pneumoniae strain type 3 were injected transcutanously into
the cisterna magna. Control rats received 150 ml PBS instead
of pneumococci. The rats were housed individually in cages,
allowed to wake up naturally, and fed with a standard diet and
water ad libitum.
Twenty-four hours after infection the rats were anesthe-
tized i.p. with 100 mg/kg thiopental (Trapanal, Byk Gulden,
Germany), tracheotomized and arti®cially ventilated with a
small animal ventilator (Model AP-10; Effenberger, Pfaf®ng,
Germany). A catheter was inserted into the left femoral artery
for continuous monitoring of mean arterial blood pressure and
for analysis of paCO2, paO2, and pH with a blood gas analyser
(IL 1304; Instrumentation Laboratory, Kirchheim, Germany).
The left femoral vein was cannulated for ¯uid substitution
and EB administration. The body temperature of the rats was
kept constant at 37.5 6 0.5°C using a rectal thermometer-
controlled heating pad. A burr hole was made at the occipital
bone and a catheter was inserted into the cisterna magna for
continuous ICP monitoring, collection of CSF samples and
determination of CSF WBC at the end of the experiment.
Determination of BBB permeability in the rat
model
For visualization of the BBB permeability during meningitis
rats were injected intravenously with 1ml of 1% (w/v) EB
(Sigma, Taufkirchen, Germany). After 1 h the brains were
perfused with 100 ml of ice-cold PBS, removed and stored at
±80°C for further histological examinations. EB was
observed under green ¯uorescence microscopy (excitation
®lter 545 nm, barrier ®lter 590 nm) and appeared red.
Rat IL-6 enyzme immunoassay
IL-6 concentration in the CSF were determined by a
commercially available immunoassay kit (Laboserv,
Staufenberg, Germany) that is speci®c for rat IL-6 and does
not cross-react with rat IL-1b, rat IL-10 and rat TNF-a. The
minimum detectable dose of rat IL-6 was 31 pg/ml. CSF
samples with enzyme levels above the detection limit were
appropriately dissolved in dilutent buffer.
Anti-IL-6 antibody
For neutralization of IL-6 bioactivity in vivo a polyclonal goat
anti-murine IL-6 antibody (R & D Systems GmbH,
Wiesbaden, Germany; <10 ng of endotoxin/mg of protein)
was diluted to a concentration of 500 mg/kg body weight in
0.5 ml of PBS and injected i.p. The ability of this antibody to
react with rat IL-6 and to neutralize IL-6 bioactivity was
demonstrated in vivo and in vitro in previous studies (Gennari
and Alexander, 1995; Shanley et al., 1997).
Rat mmunohistochemistry
Sections (10 mm thick) were ®xed with 100% ethanol.
Immunohistochemistry was performed according to the
instructions using the Vectastainâ ABC kit (Alexis
Deutschland GmbH, GruÈnberg, Germany). A polyclonal
goat anti-murine IL-6 antibody (see above) served as the
primary antibody at a dilution of 20 mg/ml at 4°C overnight.
Endogenous peroxidase activity was suppressed by incu-
bating the sections with 0.3% H2O2 in methanol for 30 min
prior to the primary antibody. The stained slides were
counterstained with Mayer's hemalum solution (Merck
Diagnostic, Darmstadt, Germany) and examined by light
microscopy.
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Competitive RT±PCR of rat MMP mRNA
For quantitation of rat MMP mRNA levels, PCR using a
multi-competitior DNA standard was performed as described
previously (Kieseier et al., 1999). Brie¯y, primer pairs for
collagenase-3, matrilysin, gelatinase A, gelatinase B, stro-
melysin-1, -2 and -3, and b-actin were used according to the
sequences published elsewhere. Poly(A+) RNA was extracted
from fozen brain specimens (n = 3) and used as a template for
cDNA snthesis using AMV reverse transcriptase (Promega,
Madison, WI, USA). Three-fold serial dilutions of competi-
tive standard cDNA were combined with a ®xed amount of
sample cDNA, and PCR was performed in 50 ml reactions
containing 200 mM dNTP, 50 pmol of sense and antisense
MMP primers, 1 U Taq DNA polymerase (Perkin Elmer,
Branchburg, NJ, USA) and 1 mCi [a-32P]dCTP (Amersham,
Braunschweig, Germany). Ten microlitres of the reaction
products were eletrophoresed on a 6% polyacrylamide gel,
exposed to appropiate screens, and the uptake of [a-32P]dCTP
within each individual PCR product was determined using a
PhosphorImaging system (Storm 360; Molecular Dynamics,
Krefeld, Germany). Levels of MMP mRNA were determined
by plotting the ratio of sample cDNA to standard DNA
against the standard dilution using a double logarithmic scale.
Experimental groups
Seven experimental groups were investigated: group 1, six
rats were injected i.c. with PBS (controls); group 2, 11 rats
were injected i.c. with pneumococci; group 3, six rats were
injected i.c. with pneumococci and treated with 500 mg/kg
anti-IL-6 antibody i.p. at the time of infection; group 4, eight
rats were injected i.c. with pneumococci and treated with
500 mg/kg anti-IL-6 antibody i.p. 6 h after infection; group 5,
three WT mice were injected i.c. with PBS (controls); group
6, ®ve WT mice were injected i.c. with pneumococci; group
7, eight IL-6±/± mice were injected i.c.with pneumococci.
Statistical analysis
All values are expressed as mean 6 SEM. Data sets of group
1 and 2, and 6 and 7 (BBB permeability index) were
compared using the unpaired Student's t-test. Data sets of
group 2, 3 and 4, and 5, 6 and 7 (CSF WBC count) were
compared using one-way ANOVA (analysis of variance) and
Scheffe's test. Differences were considered signi®cant at
P < 0.05.
Results
IL-6 is an anti-in¯ammatory cytokine in
meningitis
I.c. injection of pneumococci caused a signi®cant increase of
CSF-IL-6 levels in rats after 24 h (P < 0.05) compared with
uninfected controls (Fig. 1A). Immunohistochemistry was
performed on brain sections after pneumococcal challenge
and in controls, respectively. During meningitis IL-6 was
localized predominantly in the leptomeningeal space sur-
rounding pial vessels, but also in the underlying cortical
parenchyma (Fig. 1C). No IL-6 could be detected in controls
with this method (Fig. 1B).
Pneumococcal challenge in C57Bl/6 WT mice signi®-
cantly increased CSF WBC count after 24 h (P < 0.05)
compared with uninfected controls (Fig. 2A). Similar results
were obtained in rats challenged i.c. with pneumococci or
PBS (controls), respectively (Fig. 2B). In IL-6±/± mice, i.c.
injection of pneumococci caused a signi®cant increase in CSF
WBC count, which was almost three times higher than in
infected WT mice (P < 0.05) (Fig. 2A). Likewise, rats treated
systemically with neutralizing antibodies against IL-6
showed an increased in¯ammatory response. Irrespective of
the time of administration (15 min before or 6 h after
infection), antibody treatment augmented meningitis-induced
CSF pleocytosis by ~35% (not signi®cant), showing a trend to
an increased in¯ammatory response (Fig. 2B). These data
demonstrate that IL-6 acts as an anti-in¯ammatory cytokine
in bacterial meningitis suppressing the migration of leuko-
cytes into the CSF space.
Cerebral TNF-a, IL-1b and MIP-2 expression
are increased in the absence of IL-6 during
bacterial meningitis
To determine the reasons for the increased leukocyte count in
the infected IL-6±/± mice we investigated the changes of
cerebral expression of TNF-a, IL-1b, GM-CSF and MIP-2
using RT±PCR 24 h after injection of pneumococci and PBS,
respectively. No expression of TNF-a and IL-1b mRNA was
found in uninfected WT and IL-6±/± mice (data not shown),
whereas profound differences in the basal mRNA content of
GM-CSF and MIP-2 were detected between the two strains
(Fig. 3A). GM-CSF expression in IL-6 ±/± mice was approxi-
mately twice that in WT mice, whereas MIP-2 mRNA was
almost absent (Fig. 3A).
Meningitis caused the induction of cerebral mRNA
expression of all investigated cytokines/chemokines in WT
as well as in IL-6±/± mice after 24 h. Both, TNF-a and IL-1b
mRNA expression were increased in infected WT and IL-6±/±
mice (Fig. 3B). However, the elevation of the mRNA content
was more pronounced in IL-6±/± mice compared with infected
WT mice, indicating that the lack of IL-6 promotes the
expression these pro-in¯ammatory cytokines (Fig. 3B).
Similar results were found among the chemokines. Since
the basal gene expression of GM-CSF and MIP-2 was
different in both strains, the ratio of mRNA levels in infected
versus uninfected mice was calculated to assess the impact of
IL-6 on mRNA expression. GM-CSF mRNA content in the
brain was more than eight times higher in infected WT mice
compared with WT controls, whereas in IL-6±/± mice GM-
CSF expression was increased only more than four times
(Fig. 3C). These data indicate that GM-CSF mRNA
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upregulation is attenuated in the absence of IL-6 during
bacterial meningitis.
In contrast, cerebral MIP-2 expression was 38 times higher
in infected IL-6±/± mice, compared with a two-fold increase in
infected WT mice (Fig. 3C). These results suggest that IL-6
downregulates MIP-2 mRNA expression during bacterial
meningitis.
IL-6 increases BBB permeability and ICP
BBB permeability in mice was assessed by measuring the
permeability index using EB as a marker for extravasation of
serum proteins. Bacterial meningitis in control mice caused
leakage of cerebral blood vessels as demonstrated by an
increase in the permeability index and a signi®cant increase
in ICP 24 h after infection (P < 0.05) (Fig. 4A and B). In
infected IL-6±/± mice, however, the rise in ICP was signi®-
cantly attenuated to almost basal levels (P < 0.05), and the
Fig. 1 IL-6 expression during bacterial meningitis. (A) I.c. injection of pneumococci signi®cantly increased IL-6 levels in the CSF of rats
after 24 h. Localization of IL-6 by immunohistochemistry: (B) no IL-6 expression could be detected in controls; (C) in contrast, strong
staining for IL-6 was evident in infected rats in the leptomeningeal space surrounding pial vessels (white arrows) and in the underlying
cortical parenchyma (black arrows). *P < 0.05 compared with controls. Data are expressed as mean + SEM. Bar = 50 mm.
Fig. 2 IL-6 is an anti-in¯ammatory cytokine in bacterial
meningitis. (A) CSF WBC count was signi®cantly higher in IL-6
de®cient mice (IL-6±/±) compared with WT mice 24 h after
infection. (B) Similar results were obtained in rats challenged i.c.
with pneumococci and treated with neutralizing antibodies against
IL-6. Irrespective of the time of administration (15 min before or
6 h after infection) antibody treatment augmented meningitis-
induced CSF pleocytosis (not signi®cant). *P < 0.05 compared
with controls; #P < 0.05 compared with infected WT. Data are
expressed as mean + SEM.
Fig. 3 Expression of TNF-a, IL-1b, GM-CSF and MIP-2 mRNA
in brain specimens. (A) Differences in the basal mRNA content of
GM-CSF and MIP-2 were found between uninfected WT and
IL-6±/± mice. GM-CSF mRNA expression in uninfected IL-6±/±
mice was increased approximately twice compared with control
WT mice, whereas MIP-2 was almost absent in IL-6±/± mice.
(B) Meningitis induced the expression of TNF-a and IL-1b
mRNA in WT mice, which was further increased in IL-6±/± mice,
indicating an enhanced in¯ammatory response. No message for
these cytokines was found in uninfected controls in either strains.
(C) To assess the impact of IL-6 on gene expression during
meningitis the ratio of mRNA content in infected versus
uninfected mice was calculated. MIP-2 expression was 16-fold
increased in IL-6±/± mice compared with WT mice, whereas
GM-CSF message was almost 50% reduced in infected IL-6±/±
mice compared with infected WT mice. Data are expressed as
mean + SEM.
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permeability index was signi®cantly decreased (P < 0.05),
indicating that vascular leak was prevented in these mice
(Fig. 4A and B).
These ®ndings were con®rmed in rats treated with
neutralizing anti-IL-6 antibodies. BBB permeability was
assessed using ¯uorescence microscopy to detect cerebral
extravasation of systemically administered EB. Only minor
EB leakage was detectable in the leptomeningeal space and
no dye was found in the brain parenchyma, demonstrating an
intact BBB in control rats (Fig. 4D). Bacterial meningitis
caused exudation of EB into the subarachnoidal space and the
underlying cerebral parenchyma 24 h after infection indicat-
ing the disruption of the BBB (Fig. 4E). Extravasation of EB
was attenuated in anti-IL-6 antibody-treated rats, showing
only weak ¯uorescence in the subarachniodal space and no
¯uorescence in the brain parenchyma (Fig. 4F). Meningitis-
induced breakdown of the BBB was associated with a
signi®cant increase in ICP in untreated rats (P < 0.05)
(Fig. 4C). Treatment with anti-IL-6 antibodies before or 6 h
after infection signi®cantly reduced the increase in ICP to the
same extent (P < 0.05) (Fig. 4C).
To con®rm the direct impact of IL-6 on cerebral vessel
permeability, recombinant human IL-6 was injected stereo-
tactically into the cortex of WT mice. Extravasation of
intravenously injected EB was evident 1 h after recombinant
human IL-6 application, indicating increased BBB permea-
bility at the site of injection (Fig. 5A). No EB ¯uorescence
could be detected in the contralateral PBS-injected control
hemisphere (Fig. 5B). Together with the ®ndings described
above, these results demonstrate that IL-6 plays an important
role in the breakdown and sustained opening of the BBB.
Expression of MMPs is not mediated by IL-6
In previous studies we have shown that expression of MMPs,
especially MMP-9, is associated with disruption of BBB in
Fig. 4 IL-6 increases BBB permeability during pneumococcal meningitis. (A) I.c. injection of pneumococci increased BBB permeability
index in WT mice which was signi®cantly reduced in infected IL-6±/± mice (*P < 0.05 compared with infected WT). (B) Disruption of the
BBB in infected WT mice was associated with a signi®cant increase in ICP. However, in infected IL-6±/± mice the ICP was signi®cantly
reduced to almost normal levels (*P < 0.05 compared with WT controls; #P < 0.05 compared with infected WT mice). (C) Similar results
were obtained when rats, challenged with pneumococci, were treated with neutralizing anti-IL-6 antibodies. Irrespective of the time of
administration (before or 6 h after infection), anti-IL-6 antibody treatment signi®cantly reduced the pneumococci-induced increase in ICP
(*P < 0.05 compared with uninfected controls; #P < 0.05 compared with infected, untreated rats), which was accompanied by a
diminished BBB permeability as assessed by EB extravasation. (D) Only minor EB leakage was detectable in the leptomeningeal space
and no dye was found in the brain parenchyma demonstrating an intact BBB in control rats. (E) Meningitis caused leakage of EB into the
subarachnoidal space and the underlying cerebral parenchyma 24 h after infection. (F) Extravasation of EB was attenuated in anti-IL-6
antibody-treated rats, showing only weak ¯uorescence in the subarachniodal space and no ¯uorescence in the brain parenchyma. Data are
expressed as mean + SEM. Bar = 50 mm.
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bacterial meningitis (Paul et al., 1998; Kieseier et al., 1999).
Therefore, we investigated the effect of IL-6 on the menin-
gitis-induced expression of different MMPs in rat brains
using competitive quantitative RT±PCR. Similar to the
results shown in a previous study (Kieseier et al., 1999), we
found constitutive expression of stromelysin-3 (MMP-11),
gelatinase A (MMP-2) and matrilysin (MMP-7) at low levels,
and no expression of stromelysin-2 (MMP-10). None of these
MMPs was upregulated 24 h after infection (data not shown).
Expression of stromelysin-1 (MMP-3), which was previously
proven to be increased 6 and 9 h after infection (Kieseier et al.,
1999), was no longer upregulated after 24 h (data not shown).
However, cerebral mRNA expression of gelatinase B (MMP-
9) (Fig. 6A) and collagenase-3 (MMP-13) (Fig. 6B) was
increased in infected rats at 24 h. Pre-treatment with
neutralizing anti-IL-6 antibody did not in¯uence the expres-
sion of these MMPs (Fig. 6A and B) or the activity of MMP-9
as assessed by zymography (data not shown). These data
indicate that IL-6 does not mediate the expression or activity
of MMPs during bacterial meningitis.
Discussion
A major complication of bacterial meningitis is an increased
permeability of the cerebral microvessels, resulting in
vasogenic brain oedema and a rise in ICP (P®ster et al.,
1999). The breakdown of the BBB was always considered to
be the consequence of the invasion of leukocytes releasing
cytokines, reactive oxygen species and proteases, leading to
an increase in vascular permeability. Here we show that IL-6
contributes substantially to the disruption of the BBB, but at
the same time acts as an anti-in¯ammatory cytokine in
bacterial meningitis. These ®ndings demonstrate that the
migration of leukocytes across the BBB and the increase in
vascular permeability are two independent processes.
Bacterial meningitis in IL-6±/± mice caused a three-fold
increase in CSF WBC count compared with infected WT
mice, which was associated with increased TNF-a, IL-1b and
MIP-2 mRNA expression. TNF-a and IL-1b are well-
characterized pro-in¯ammatory cytokines in bacterial men-
ingitis and both can initiate meningeal in¯ammation (Ramilo
et al., 1990). Our study shows that IL-6 attenuates mRNA
expression of both cytokines, indicating that IL-6 acts as an
anti-in¯ammatory cytokine. Similar results were found by
others who documented increased TNF-a and IL-1b protein
expression in IL-6±/± mice during acute in¯ammation (van der
Poll et al., 1997; Xing et al., 1998), af®rming the anti-
in¯ammatory nature of IL-6. MIP-2, which parallels the
action of IL-8 in humans (Broxmeyer et al., 1996), is a
member of the CXC family of chemokines and a potent
chemoattractant of polymorphonuclear neutrophils (PMN)
(Lahrtz et al., 1998). MIP-2 was shown to be an important
mediator of PMN in¯ux in many in¯ammatory diseases such
as ocular bacterial infection and urinary tract infection (Hang
et al., 1999; Kernacki et al., 2000). The importance of MIP-2
in attracting PMN during bacterial meningitis was demon-
strated in in vitro (Spanaus et al., 1997) and in vivo (Diab
et al., 1999) studies, which proved that neutralization of
MIP-2 attenuated neutrophil chemotaxis. Our study is in
accordance with results obtained by others (Xing et al., 1998;
Hurst et al., 2001) who showed the regulatory role of IL-6
during acute in¯ammation where MIP-2 mRNA and protein
expression was increased in IL-6±/± mice compared with WT
mice, resulting in an enhanced neutrophilic response. It was
also shown that IL-6 can attenuate the TNF-a- and IL-1b-
mediated release of IL-8 (Hurst et al., 2001), the human
homologue of MIP-2, which might explain the increase of
MIP-2 in infected IL-6±/± mice. The elevated number of
leukocytes cannot be accounted for by the prolongation of the
lifetime of these cells, since the absence of IL-6 does not
affect the percentage of apoptotic neutrophils during in¯am-
mation, as shown by others (Brach et al., 1992; Xing et al.,
1998). The highly reduced mRNA expression of MIP-2 in
uninfected IL-6±/± compared with WT controls found in our
study also suggests that the basal expression of this pro-
in¯ammatory chemokine is compensatorily downregulated to
counteract the absence of the anti-in¯ammatory IL-6.
Fig. 6 Expression of MMP-9 and MMP-13 mRNA in rats treated
with anti-IL-6 antibodies. Cerebral infection of rats with
pneumococci caused an increase in (A) MMP-9 and (B) MMP-13
mRNA expression compared with uninfected controls. No
reduction in mRNA levels were found in infected rats pre-treated
with anti-IL-6 antibodies. Data are expressed as mean + SEM.
Fig. 5 Effect of IL-6 on BBB permeability. (A) Direct injection of
recombinant human IL-6 into the cerebral cortex of WT mice
increased vessel permeability as assessed by extravasation of
systemically administered EB. (B) No EB leakage was detected in
the contralateral side, which was injected with PBS. Bar = 100 mm.
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On the other hand, expression of GM-CSF in infected
IL-6±/± mice was also reduced compared with infected WT
mice. GM-CSF can directly act on PMN by modulating the
surface expression of adhesion molecules and increasing
neutrophil adherence to the endothelium (Arnaout et al.,
1986). It was shown that GM-CSF can induce the expression
of IL-6 in monocytes and microglia (Suzumura et al., 1996)
and that vice versa IL-6 can inhibit GM-CSF gene expression
(Kremlev et al., 1998), presenting a negative feedback system
which might explain the fact that the basal GM-CSF mRNA
level in uninfected IL-6±/± mice was more than twice that in
WT controls. Therefore, it was surprising that the increase in
GM-CSF mRNA expression was attenuated in infected IL-
6±/± mice, compared with infected WT mice. However,
similar results were observed in IL-6±/± mice after a focal cryo
brain injury, which showed reduced GM-CSF protein
expression compared with injured WT controls (Penkowa
et al., 1999). Despite the reduced GM-CSF expression in the
absence of IL-6 we found higher CSF WBC counts in infected
IL-6±/± mice compared with infected WT mice, con®rming
the results of a previous study which demonstrated that
neutrophilic in®ltration in lungs of GM-CSF-de®cient mice is
increased after pulmonary streptococcal infection (LeVine
et al., 1999). It is unclear whether the increased in¯ammatory
response is directly related to the reduced GM-CSF expres-
sion or is an indirect effect of GM-CSF on other chemokines.
For example, it was shown that MIP-2 levels are elevated in
GM-CSF±/± mice with pulmonary streptococcal infection
compared with infected WT mice (LeVine et al., 1999),
indicating that GM-CSF can downregulate MIP-2 expression.
Therefore, we suggest that decreased GM-CSF expression in
IL-6±/± mice also might have contributed to the enhanced CSF
pleocytosis during bacterial meningitis by increasing MIP-2
expression.
Despite the fact that leukocyte recruitment was enhanced
in infected IL-6±/± mice and IL-6 antibody-treated rats, the
disruption of the BBB was signi®cantly reduced, suggesting
that transmigration of leukocytes and increase in vascular
permeability are two independent processes. In this study we
demonstrated the direct impact of IL-6 on cerebral vessel
permeability by injecting the cytokine directly into the brain.
There are several other studies which showed that IL-6
in¯uences the integrity of the BBB. For example, IL-6 was
demonstrated to reduce the transendothelial electrical resist-
ance (de Vries et al., 1996) and to induce changes in the
morphology and permeability of endothelial cells in an
in vitro model of the BBB (Duchini et al., 1996). Moreover,
the systemic administration of IL-6 increased the permeabil-
ity of the BBB in rats (Saija et al., 1995), and transgenic mice
overexpressing IL-6 in astrocytes showed extensive extra-
vasation of horseradish peroxidase indicating an open BBB
(Brett et al., 1995).
Previously, we demonstrated that MMPs, especially MMP-
9, are involved in the disruption of the BBB and oedema
formation during bacterial meningitis (Paul et al., 1998;
Kieseier et al., 1999). Therefore, we reasoned that IL-6 might
regulate MMP expression or activity. However, in this study
no reduction in the expression of MMP-9 and MMP-13 or
activity of MMP-9 was found, despite the signi®cant decrease
in vascular permeability in rats treated with anti-IL-6
antibodies. These results suggest that MMPs may not be
directly involved in the disruption of the BBB. It seems that
MMPs mediate the migration of leukocytes rather than
directly disturb endothelial barrier function, and that the
bene®cial effect of MMP-inhibition on brain oedema forma-
tion might be secondary to its anti-in¯ammatory effect. These
results are in accordance with in vitro studies showing that
increased endothelial permeability is a not necessary con-
sequence of PMN migration (Huang et al., 1988; Lennon
et al., 1998). Our ®ndings rather suggest that IL-6 is released
by migrating leukocytes and/or activated resident cells, which
in turn increases cerebral vascular permeability contributing
to the formation of brain oedema during bacterial meningitis.
Taken together, the results of this study show that IL-6
increases BBB permeability during bacterial meningitis,
causing the formation of brain oedema, but inhibits leukocyte
recruitment possibly by suppressing the expression of TNF-a,
IL-1b and MIP-2. Dissecting the downstream signalling
pathways of IL-6 affecting leukocyte migration or vascular
permeability will be helpful to better understand the
pathophysiology of bacterial meningitis and other in¯amma-
tory diseases.
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